Actinium Pharmaceuticals, Inc.

Total Valuation

Actinium Pharmaceuticals, Inc. carries a market capitalization of 44.29M, placing it among publicly traded companies globally. Its enterprise value stands at -4.38M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Actinium Pharmaceuticals, Inc. currently has 31.37M shares outstanding.

Valuation Ratios

Actinium Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 2.71. The price-to-sales ratio is 0.87, and the price-to-book ratio stands at 1.01.

Enterprise Valuation

Financial Position

Actinium Pharmaceuticals, Inc. maintains a current ratio of 4.08, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Actinium Pharmaceuticals, Inc. posts a return on equity of 45.86 and a return on invested capital of 36.79.

Stock Price Statistics

Actinium Pharmaceuticals, Inc.'s stock has declined approximately -7.33553% over the past 52 weeks. The 50-day moving average sits at 1.11, while the 200-day moving average is 1.12.

Income Statement

Over the trailing twelve months, Actinium Pharmaceuticals, Inc. generated 35.09M in revenue and converted that into 11.31M in net income, yielding earnings per share of 0.36. EBITDA reached 10.43M, while operating income came in at 9.56M.

Balance Sheet

Actinium Pharmaceuticals, Inc. holds 36.47M in cash and equivalents against 1.34M in total debt, resulting in a net debt position of -36.47M. Total book value stands at 30.30M, with working capital of 28.48M providing operational flexibility.

Cash Flow

Actinium Pharmaceuticals, Inc. produced -22.66M in operating cash flow over the past twelve months. After subtracting -584,000.00 in capital expenditures, free cash flow totaled -23.25M - equivalent to -0.74 per share.

Margins

Actinium Pharmaceuticals, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 27.23 and net profit margin of 32.23 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Actinium Pharmaceuticals, Inc.'s most recent stock split took place on August 11, 2020 with a 30:1 split ratio.

Scores

Actinium Pharmaceuticals, Inc. posts an Altman Z-Score of -9.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.